Navigation Links
Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
Date:8/8/2008

ASHBURN, Va., Aug. 8 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the first of three ongoing phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the management of post-operative pain.

Innocoll's BUPIVACAINE SURGICAL IMPLANT is a biodegradable and fully bioresorbable matrix of purified fibrillar collagen impregnated with the local anesthetic, bupivacaine, which has been specifically developed and formulated using Innocoll's proprietary CollaRx sponge technology. It is under development in the US and Europe for the management of post-operative pain following moderate/major abdominal, gynecological, abdominal, thoracic, and orthopedic surgeries.

Post-operative pain is typically controlled with narcotic analgesics such as morphine, but systemic administration of these drugs can result in unfavorable side effects including suppression of breathing, sedation, nausea and vomiting, and can also affect patient recovery. Innocoll's BUPIVACAINE SURGICAL IMPLANT is intended to provide pain control directly at the surgical site and thus reduce the level of additional analgesia required following surgery. The collagen matrix naturally biodegrades over a few days and the bupivacaine is released to provide local analgesia for up to 96 hours post-operatively. A key feature of Innocoll's product is the ability to implant it directly into the surgical cavity and at different layers within the wound, such as across the peritoneal incision and directly below the skin incision, which enables localized treatment of both the incisional and deep, visceral pain components normally associated with moderate and major surgery. The bioresorbable nature of the collagen matrix also offers significant clinical benefits and convenience advantages over ambulatory infusion pumps which can be used to pro
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
3. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
5. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
7. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
10. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
11. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... THE WOODLANDS, Texas , March 2, 2015 /PRNewswire/ ... ), a biopharmaceutical company focused on developing breakthrough treatments ... year end 2014 financial results on Wednesday, March 4, ... hold a conference call and webcast to discuss clinical ... and year end of 2014 at 10:00 a.m. Eastern ...
(Date:3/2/2015)... LOS ANGELES , March 2, 2015 ImmunoCellular Therapeutics, ... report financial results for the year ended December 31, 2014 on ... update conference call and webcast on Thursday, March 12, 2015, at ... Gengos , President and CEO.   , ... international dial-in: (631) 291-4544; conference code 92238648. , , , ...
(Date:3/1/2015)... , March 1, 2015 /CNW Telbec/ -   Ergoresearch ... Laval and known under the « Équilibre, ... for the second quarter Ended on December 31, 2014. ... Canadian currency. Revenues for the second ... 31, 2014 totaled $ 4 095 112 decreasing by 8,8 % compared ...
Breaking Medicine Technology:Lexicon To Report Fourth Quarter And Year End 2014 Financial Results On March 4, 2015 2ImmunoCellular Therapeutics to Report 2014 Financial Results on March 9, 2015; a Business Update Conference Call and Webcast is Scheduled for March 12, 2015 2Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 2Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 3Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 4
(Date:3/2/2015)... March 02, 2015 Robins & Morton ... conjunction with Women in Construction Week (March 1-7, sponsored ... NAWIC) and National Women’s History Month, Robins & Morton ... affect the company and the construction industry as a ... to the dozens of roles in between, each woman ...
(Date:3/2/2015)... The Workgroup for Electronic Data Interchange (WEDI), ... health IT to create efficiencies in healthcare information exchange, ... Providers.” The white paper by WEDI’s ICD-10 Testing Subworkgroup ... testing by focusing on primary considerations and steps for ... October 1, 2015 implementation date. Download the white ...
(Date:3/2/2015)... This year, the National Multiple Sclerosis Society’s annual ... for people across the country to unite, raise awareness, ... live their best lives. MS Awareness Week is a special ... join the Society’s vision of a world free of MS. ... of the central nervous system, interrupts the flow of information ...
(Date:3/2/2015)... March 02, 2015 Four Seasons Resort Maui ... its 25th anniversary this year, having officially opened its doors ... luxury resort is honoring over 70 employees who started on ... from amongst the approximately 400 original employees. The celebration ... Oceanfront Lawn. , This Four Seasons flagship resort, ...
(Date:3/2/2015)... March 02, 2015 What are the ... physicians request references? When are interviews scheduled, how can ... opportunities?, Both training and practicing physicians who are looking ... questions and more at the PracticeLink Physician Career Advancement ... drop-in Job Fair is from 5:30 to 8:30 p.m. ...
Breaking Medicine News(10 mins):Health News:Robins & Morton Recognizes Women In Construction 2Health News:WEDI Releases New White Paper on ICD-10 Testing for Small Providers 2Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2
... , , Hospitals, ... , PRINCETON, N.J., Aug. 18 Twelve New ... federal government to test an innovative new incentive method that aims ... , The three-year trial program could serve as a ...
... KONG, Aug. 18 IBM (NYSE: IB M ... Life Insurance Company Limited (NYSE: CI ), has implemented ... continuity in the event of disasters or other incidents that could ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090416/ I BMLOGO ) ...
... 18 EwingCole, a nationally recognized architectural, engineering, interior ... today announced that it will combine its practice with ... with a robust portfolio of healthcare projects. The ... September 1, 2009, will create the Delaware Valley,s largest ...
... , , ... systems for targeted, less-invasive medical treatments, today announced that Massachusetts ... iCT, making it second in the nation and third in ... successfully integrate intra-operative imaging -- from high-field MRI to multi-slice ...
... , ARLINGTON, Va., Aug. 18 "Proposed ... add billions of dollars of un-reimbursed cost to the Medicare ... K.C. McAlpin, executive director of ProEnglish, a national organization that ... the United States. , , The ...
... ELM GROVE, Wis., Aug. 18 Long wait times can ... safety . Many hospitals constantly struggle with moving patients in need of critical ... bed. Compirion Healthcare Soluti o ns is ... Improving Patient Flow - ED to Inpatient , free of charge ...
Cached Medicine News:Health News:Medicare Picks N.J. to Test Innovative Incentive System 2Health News:Medicare Picks N.J. to Test Innovative Incentive System 3Health News:Medicare Picks N.J. to Test Innovative Incentive System 4Health News:CIGNA Provides Peace-of-mind for APAC Customers by Ensuring Business Continuity and Resilience with IBM 2Health News:CIGNA Provides Peace-of-mind for APAC Customers by Ensuring Business Continuity and Resilience with IBM 3Health News:CIGNA Provides Peace-of-mind for APAC Customers by Ensuring Business Continuity and Resilience with IBM 4Health News:EwingCole, RDLA Join Together, Creating Architecture/Engineering Firm With Largest Healthcare Focus in the Delaware Valley 2Health News:EwingCole, RDLA Join Together, Creating Architecture/Engineering Firm With Largest Healthcare Focus in the Delaware Valley 3Health News:Massachusetts General Hospital is Second in Nation to Acquire Both BrainSUITE(R) iMRI and iCT 2Health News:Free Compirion Bed Flow Webinar Helps Improve Patient Flow From ED to Inpatient Units 2Health News:Free Compirion Bed Flow Webinar Helps Improve Patient Flow From ED to Inpatient Units 3
For the quantitative determination of Creatine Kinase in serum....
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C....
For the quantitative determination of total glucose in serum....
Intended for the quantitative determination of glucose in serum. Reaction: endpoint. Wavelength: 500 nm. Linearity: 500 mg/dL (27.8 mmol/L)....
Medicine Products: